A relative reduction in mid-follicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates
- PMID: 16785261
- DOI: 10.1093/humrep/del219
A relative reduction in mid-follicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates
Abstract
Background: The effect of early- and mid-follicular LH concentrations on the ovarian response and pregnancy outcomes was evaluated in women receiving pituitary down-regulation with a GnRH agonist and ovarian stimulation with recombinant FSH (rFSH) during IVF/ICSI treatment.
Methods: Blood samples were collected prospectively from 701 cycles (560 patients) of assisted reproduction and analysed retrospectively. On the basis of LH concentrations on stimulation day 7/8, the patients were divided into two groups: LH<1.2 IU/l (n=179) and LH>or=1.2 IU/l (n=522). Cycle outcomes were also compared on the basis of a ratio of mid- to early-follicular LH concentrations (<or=0.5, n=210; >0.5, n=491).
Results: Patients with low LH concentrations were found to have a significant reduction in the late-follicular estradiol concentrations (P<0.001), the number of oocytes retrieved (P<0.01) and the number of usable embryos (P<0.01), and they required significantly more rFSH (430 IU difference, P<0.01). These differences did not translate into a significant change in live birth rates. Conversely, a ratio of <or=0.5 mid- to early-follicular LH concentrations (a reduction of >or=50%) was associated with a significant reduction in live birth rates per embryo transfer and per cycle started (27.3 versus 19.0%, P<0.05 and 22.2 versus 15.8%, P<0.05, respectively).
Conclusions: Low mid-follicular levels of LH have a significant impact on ovarian response but not on live birth rates. A fall in LH level of >or=50% from the early- to mid-follicular phase resulted in a lower live birth rate.
Similar articles
-
IVF/ICSI outcome and serum LH concentration on day 1 of ovarian stimulation with recombinant FSH under pituitary suppression.Hum Reprod. 2005 Sep;20(9):2441-7. doi: 10.1093/humrep/dei101. Epub 2005 May 26. Hum Reprod. 2005. PMID: 15919773
-
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone.Fertil Steril. 2005 Jan;83(1):42-8. doi: 10.1016/j.fertnstert.2004.06.050. Fertil Steril. 2005. PMID: 15652885
-
GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.Hum Reprod. 2005 May;20(5):1213-20. doi: 10.1093/humrep/deh765. Epub 2005 Mar 10. Hum Reprod. 2005. PMID: 15760966 Clinical Trial.
-
The clinical significance of the retrieval of a low number of oocytes following mild ovarian stimulation for IVF: a meta-analysis.Hum Reprod Update. 2009 Jan-Feb;15(1):5-12. doi: 10.1093/humupd/dmn053. Hum Reprod Update. 2009. PMID: 19091754 Review.
-
[Optimizing ovarian stimulation for IVF using GnRH antagonists].J Gynecol Obstet Biol Reprod (Paris). 2004 Oct;33(6 Pt 2):3S42-5. J Gynecol Obstet Biol Reprod (Paris). 2004. PMID: 15643688 Review. French.
Cited by
-
Ovarian response determines the luteinizing hormone suppression threshold for patients following the gonadotrophin releasing hormone antagonist protocol: A retrospective cohort study.Heliyon. 2023 Dec 20;10(1):e23933. doi: 10.1016/j.heliyon.2023.e23933. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38187350 Free PMC article.
-
LH level on the antagonist administration day as a predictor of the reproductive outcomes in women with normal ovarian function.Front Endocrinol (Lausanne). 2023 Sep 19;14:1232361. doi: 10.3389/fendo.2023.1232361. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37795370 Free PMC article.
-
Effect of Exogenous Luteinizing Hormone (LH) Supplementation on Clinical Pregnancy of Patients Receiving Long-Acting Gonadotropin-Releasing Hormone Agonist (GnRHa) Cycles: A Retrospective Cohort Study.Int J Womens Health. 2022 Dec 13;14:1691-1700. doi: 10.2147/IJWH.S388726. eCollection 2022. Int J Womens Health. 2022. PMID: 36536609 Free PMC article.
-
Luteinizing hormone-based modified GnRH antagonist protocol in normal responders undergoing in vitro fertilization treatment: A multi-center randomized controlled trial.Front Endocrinol (Lausanne). 2022 Aug 11;13:922950. doi: 10.3389/fendo.2022.922950. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36034460 Free PMC article. Clinical Trial.
-
Luteinizing hormone supplementation in women with hypogonadotropic hypogonadism seeking fertility care: Insights from a narrative review.Front Endocrinol (Lausanne). 2022 Aug 1;13:907249. doi: 10.3389/fendo.2022.907249. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35979440 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
